This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Research of Molecular and Metabolic Markers in Oligodendrogliomas Comparatively to Other Brain Tumours

This study has been completed.
Information provided by:
University Hospital, Strasbourg, France Identifier:
First received: September 13, 2005
Last updated: August 29, 2011
Last verified: August 2011
At present, diagnosis of oligodendroglioma is made on histological and radiographic criteria in the French Mayo-Ste Anne classification. The less frequent grade A oligodendrogliomas are characterized by no vascular contrast on RMN evaluation comparatively to grade B forms. This benign histological subtype relapses in few cases with a more aggressive histology. To determine these relapsed cases at diagnosis, a collection of tumour begun in February 2004. Then, our study was designed to identify diagnostic molecular and metabolic markers that could eventually be used as a signature characterising grade A versus grade B oligodendrogliomas. The molecular analysis will use genomic techniques like allelotyping study, quantitative real-time PCR, gene sequencing , serial analysis of genomic expression and immunohistochemistry, since the metabolic study will be the spectroscopic examination of in vivo tumour. This study will include paediatric and adult patients followed for oligodendrogliomas, medulloblastomas and gliomas to compare the different tumour signatures. All these results will be correlated to survival and clinical features.


Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Research of Molecular and Metabolic Diagnostic Markers in Oligodendrogliomas A and B Comparatively.

Resource links provided by NLM:

Further study details as provided by University Hospital, Strasbourg, France:

Enrollment: 189
Study Start Date: February 2004
Study Completion Date: August 2011

Ages Eligible for Study:   1 Year and older   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patient with oligodendroglioma or medulloblastoma or glioma

Inclusion Criteria:

  • Paediatric and adult patients (> 1 year of age)
  • Patient with oligodendroglioma or medulloblastoma or glioma
  • Possibility of 3 year follow-up
  • Patient consent obtained

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00213876

Natacha Entz-Werle
Strasbourg, France
Sponsors and Collaborators
University Hospital, Strasbourg, France
Principal Investigator: Natacha Entz-Werle, MD Hopitaux Universitaires de Strasbourg
  More Information Identifier: NCT00213876     History of Changes
Other Study ID Numbers: 3154
Study First Received: September 13, 2005
Last Updated: August 29, 2011

Keywords provided by University Hospital, Strasbourg, France:
Brain tumours
Presence of molecular abnormalities statistically linked to survival or response to chemotherapy

Additional relevant MeSH terms:
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue processed this record on September 20, 2017